65,437 trials
Neoplasms · Metastatic Cancer · Advanced Cancer
Primary: Part A: Number of Participants With Dose-limiting Toxicity (DLT) — 2; 0 Participants
Surgical Site Infection
Primary: Culture Positivity — 14; 13; 63; 63 Participants
Pulmonary Arterial Hypertension
Primary: Change in Exercise Capacity at Month 12 — 22.0 meters
Alzheimer Disease, Early Onset · Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 315; NA; 550; NA ng/mL
Hypoglycemia
Primary: Time to Plasma Glucose Recovery — 10.00; 30.00; 10.00 minutes — p=<0.001
Covid19
Primary: Recruitment Feasibility — 46 Participants
Cancer and Chemotherapy Related Anemia
Primary: Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Week 3 to Week 18 — 42; 60 Participants — p=0.0143
Anxiety · Depression · Personality Disorders
Primary: Time to Return to Heart Rate Baseline During the Regulation Period During Training — 1.591; 1.828; 1.505; 1.534475 log (seconds) — p=0.019
Psoriatic Arthritis
Primary: Number of Participants Who Are Eligible, Consent, and Complete the 48 Weeks Study — 0 Participants
Haemostasis · Haemophilia A
Primary: The Number of Bleeding Episodes During at Least 24 Weeks From Treatment Onset — 43; 13; 14 Episodes
Gastric Cancer · Gastroesophageal Junction Cancer
Primary: Overall Survival — 6.93; 7.36 Months — p=0.8596
Multiple Sclerosis
Primary: Walking Endurance — 42; 25 meters
Pre-Exposure Prophylaxis
Primary: Plasma TFV AUC0-INF GMR — 8.75; 8.27 ng*h/mL
Osteoarthritis, Hip
Primary: Percentage Ambulating Early After Spinal Anesthesia — 9; 20; 35 Participants
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Time to Additional Therapy for Uveitis — 344.0; 332.0 days — p=0.562